Pop Quiz
Which JAK Inhibitor Remains the Standard of Care in Myelofibrosis?
Myelofibrosis is a chronic myeloproliferative neoplasm characterized by debilitating symptoms and splenomegaly. Janus kinase (JAK) inhibitors improve quality of life by reducing spleen size and symptom burden. At the 2025 SOHO Annual Meeting, Junaid Anwar, MD, presented a meta-analysis of five phase 3 trials evaluating JAK inhibitors against best available therapy.
In an interview with Consultant360, Dr Anwar emphasized the relative efficacy and safety profiles of ruxolitinib, fedratinib, pacritinib, and momelotinib. The question below tests your understanding of which JAK inhibitor is currently considered the standard of care.